Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study
Annals of Hematology · 2025
DOI: 10.1007/s00277-024-06120-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Claudia Sossa-Melo und 29 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia. claudiasossa@gmail.com. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG < 2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), Low-Intensity Regimen Based on Low-Dose Cytarabine (LDAC-based) (12.6%), hypomethylating agents (HMAs, with/without venetoclax) (35.3%), and supportive care (15.2%). The overall survival (OS) rate was 35.2% at 1 year and 5.6% at 5 years (13.7% for IC, 9.4% for LDAC-based, and 0% for other treatments); with median OS of 8.2 months (10.6 months after IC, 8.8 months after non-IC, 8.9 months after azacitidine/decitabine, 8.2 months after azacitidine-venetoclax, and 1.9 months with supportive care). Only 1.5% of patients underwent a transplant in the first line. The Leukemia-free survival (LFS) rate was 45.8% at 1-year and 13.7% at 5-years (22.4% for IC, 9.4% and 0% for other treatments); with median LFS of 9.5 months (17.3 months after IC, 7.4 months after LDAC-based, and 10.8 months after HMA). This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health Sciences, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia. claudiasossa@gmail.com.
- Hematology and Hematopoietic Stem Cell Transplantation Unit, Fundación Oftalmológica de Santander (FOSCAL), Torre C - Piso 9 - Consultorio 910, Calle 158 # 20 - 95, Floridablanca, Santander, Colombia. claudiasossa@gmail…
- Clinical Funcional Unit Leukemia, Lymphoma, Myeloma, Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Bogotá, Colombia.
- Faculty of Health Sciences, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia.
- Hematology and Hematopoietic Stem Cell Transplantation Unit, Fundación Oftalmológica de Santander (FOSCAL), Torre C - Piso 9 - Consultorio 910, Calle 158 # 20 - 95, Floridablanca, Santander, Colombia.
- Programa para el tratamiento de las enfermedades hemato-oncológicas de Santander, Floridablanca, Colombia.
Zitieren
APA
Sossa-Melo, C., Abello-Polo, V., Salazar, L. A., Peña, A. M., Luna-González, M., Cuervo-Lozada, D., Quintero-Vega, G. E., Daza, J., Omaña-Orduz, O. P., Mantilla, W., Perdomo, I., Galvez, K., Díaz-Correa, L. M., Guerrero-Burbano, P. A., Herrera, J. M., Idrobo, H., Gaviria, L. M., Correa-Correa, M. E., Lobatón, J., …, & Montesinos, P. (2025). Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study. Annals of Hematology. https://doi.org/10.1007/s00277-024-06120-0
Vancouver
Sossa-Melo C, Abello-Polo V, Salazar LA, Peña AM, Luna-González M, Cuervo-Lozada D, et al. Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study. Annals of Hematology. 2025. doi:10.1007/s00277-024-06120-0
BibTeX
@article{SossaMelo2025,
author = {Sossa-Melo, Claudia and Abello-Polo, Virginia and Salazar, Luis A and Peña, Angela M and Luna-González, María and Cuervo-Lozada, Diana and Quintero-Vega, Guillermo E and Daza, Jorge and Omaña-Orduz, Olga Paola and Mantilla, William and Perdomo, Iván and Galvez, Kenny and Díaz-Correa, Laura María and Guerrero-Burbano, Paola Andrea and Herrera, Juan Manuel and Idrobo, Henry and Gaviria, L M and Correa-Correa, Mario Ernesto and Lobatón, José and Bermúdez, Carlos Daniel and Pedraza-Morales, Julian Eduardo and Serrano-Casas, Juan Carlos and Jaramillo, Francisco and Gómez, Rigoberto and Rosales, Carmen and Solano, María Helena and Varón, Carlos and Rodríguez-Veiga, Rebeca and Martínez-Cuadrón, David and Montesinos, Pau},
title = {Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-024-06120-0}
}
EUVIMED